ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:PMN) (Nasdaq:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced an oral presentation and two onsite poster presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, which will be held on April 22-27, 2023 in Boston, MA. The presentations highlight ProMIS’ broad pipeline of next-generation neurodegenerative disease therapeutics, including data that further characterize lead drug AD candidate, PMN310, as well as preclinical optimization studies of an Alzheimer’s vaccine and data supporting RACK1 as a potential target in amyotrophic lateral sclerosis (ALS).

Read more at globenewswire.com